TY - JOUR
T1 - Natural history of dilated cardiomyopathy in children
AU - Akagi, Teiji
AU - Benson, Lee N.
AU - Lightfoot, Nancy E.
AU - Chin, Kerrison
AU - Wilson, Greg
AU - Freedom, Robert M.
PY - 1991/5
Y1 - 1991/5
N2 - To assess the natural history and potential risk factors in childhood dilated cardlomyopathy, we investigated 25 patients (ages 9.6 ± 4.4 years) who presented after they were 2 years old. All patients had symptoms of congestive heart failure and reduced contractility with a dilated left ventricle at presentation. Two factors at presentation were significantly different between patients who died less than 1 year after the presentation (n = 14) and those who survived for more than 1 year (n = 9); cardiothoracic ratio (65.1% ± 6.8% vs 57.1% ± 6.1%, p < 0.01) and left ventricular ejection fraction (31.3% ± 7.0% vs 40.0% ± 6.2%, p < 0.05). Irrespective of intensive medical therapy, dilated cardiomyopathy in children had a poor prognosis; the actuarial survival rate was 41% at 1 year and 20% at 3 years. Other forms of therapy should be considered in the early stages of dilated cardiomyopathy in this high-risk group.
AB - To assess the natural history and potential risk factors in childhood dilated cardlomyopathy, we investigated 25 patients (ages 9.6 ± 4.4 years) who presented after they were 2 years old. All patients had symptoms of congestive heart failure and reduced contractility with a dilated left ventricle at presentation. Two factors at presentation were significantly different between patients who died less than 1 year after the presentation (n = 14) and those who survived for more than 1 year (n = 9); cardiothoracic ratio (65.1% ± 6.8% vs 57.1% ± 6.1%, p < 0.01) and left ventricular ejection fraction (31.3% ± 7.0% vs 40.0% ± 6.2%, p < 0.05). Irrespective of intensive medical therapy, dilated cardiomyopathy in children had a poor prognosis; the actuarial survival rate was 41% at 1 year and 20% at 3 years. Other forms of therapy should be considered in the early stages of dilated cardiomyopathy in this high-risk group.
UR - http://www.scopus.com/inward/record.url?scp=0025822172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025822172&partnerID=8YFLogxK
U2 - 10.1016/0002-8703(91)90158-E
DO - 10.1016/0002-8703(91)90158-E
M3 - Article
C2 - 2017982
AN - SCOPUS:0025822172
SN - 0002-8703
VL - 121
SP - 1502
EP - 1506
JO - American Heart Journal
JF - American Heart Journal
IS - 5
ER -